Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Vet J. 2013 Mar;195(3):319-24. doi: 10.1016/j.tvjl.2012.07.013. Epub 2012 Aug 19.
The prognostic significance of minimal residual disease (MRD) in the early phases of chemotherapy was examined in 36 dogs with multicentric high-grade B-cell lymphoma. Sequences of immunoglobulin heavy chain (IgH) gene fragments from lymphoma cells were amplified and used to design allele-specific primers and probes for real-time PCR. The dogs were treated with a 6-month modified version of the University of Wisconsin-Madison chemotherapy protocol (UW-25) and evaluated for the MRD level at weeks 6 and 11 of UW-25. Of the 31 dogs that remained on the protocol at week 11, 14 were found to be MRD negative (<10tumour cells/10(5) peripheral blood mononuclear cells [PBMCs]), whereas the other 17 were MRD positive (⩾10tumour cells/10(5) PBMCs). The progression-free survival of the dogs with MRD-negative status at week 11 (median, 337days) was significantly longer than that of the MRD-positive dogs at the same time point (median, 196days) (P=0.0002). These results indicate the clinical significance of MRD as a prognostic marker in the early phase of chemotherapy.
在 36 只患有多中心高级别 B 细胞淋巴瘤的犬中，检查了化疗早期微小残留病（MRD）的预后意义。从淋巴瘤细胞中扩增免疫球蛋白重链（IgH）基因片段，并用于设计用于实时 PCR 的等位基因特异性引物和探针。这些犬接受了威斯康星大学麦迪逊分校（UW-25）化疗方案的 6 个月改良版治疗，并在 UW-25 的第 6 周和第 11 周评估 MRD 水平。在第 11 周仍在方案中的 31 只犬中，有 14 只被发现为 MRD 阴性（<10 个肿瘤细胞/10(5)外周血单核细胞 [PBMCs]），而其他 17 只为 MRD 阳性（⩾10 个肿瘤细胞/10(5)PBMCs）。第 11 周时 MRD 阴性状态的犬的无进展生存期（中位数为 337 天）明显长于同一时间点的 MRD 阳性犬（中位数为 196 天）（P=0.0002）。这些结果表明，MRD 作为化疗早期的预后标志物具有临床意义。
